

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

**JACOBIO ANNOUNCES FIRST PATIENT DOSED IN CHINA FOR PHASE IB/III
CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN COMBINATION
WITH CHEMOTHERAPY FOR THE FIRST-LINE THERAPY FOR
KRAS-MUTANT PANCREATIC CANCER**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the first patient has been dosed in China for a Phase Ib/III clinical trial of pan-KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine for the first-line therapy of KRAS-mutant pancreatic cancer.

The initiation of this trial is supported by encouraging preliminary clinical data from the ongoing Phase I trial previously reported in the 2025 annual report of the Company. As of the data cutoff date of January 15, 2026, a total of 42 patients with solid tumours (all treated with second-line or later regimens) had been enrolled in China. Grade 3 treatment-related adverse events (TRAEs) occurred in 11.9% (5/42) of patients; no Grade 4 or 5 TRAEs were observed, and no Grade 3 or higher adverse reactions including rash, mucositis, nausea, vomiting, or diarrhea were reported. Within the predicted effective dose range of ≥ 160 mg daily, the objective response rate (ORR) was 38.5% among 13 evaluable pancreatic cancer patients (including 2 second-line patients, and the remaining receiving third-line or later therapy), confirming the drug’s favorable safety profile and robust preliminary antitumor activity.

JAB-23E73 is an orally available pan-KRAS inhibitor independently developed by the Company. The Company licensed JAB-23E73 exclusively to AstraZeneca (LSE/STO/NYSE: AZN) on a worldwide basis except for the People's Republic of China (excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan). With regard to Chinese Mainland, the two parties shall jointly develop and co-commercialise JAB-23E73. KRAS mutations are highly prevalent in pancreatic cancer. The initiation of this study represents an important milestone in the development of JAB-23E73.

ABOUT JACOBIO

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around targeted oncology and tumor immunotherapy with pipelines in KRAS, Sting, P53 and MYC pathways. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our targeted antibody-drug conjugate (tADC) and immunostimulatory antibody-drug conjugate (iADC) Platform loaded with targeted drugs and immune recruiters as payloads.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that JAB-23E73 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, July 20, 2026

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.